Trisalus Life Sciences (TLSI) Canaccord Genuity's 46th Annual Growth Conference summary

Technology and innovation

• Developed a smart valve catheter technology that enhances drug delivery to solid tumors by 50% to 500% and reduces off-target complications, improving patient outcomes and cost savings.

• The technology addresses high intratumoral pressure, enabling effective therapy even in tumors with pressures exceeding normal blood pressure.

• Focused on liver embolizations but applicable to a wide range of vascular anatomies and tumor types.

• Received a new G-code, supporting reimbursement across all care sites and facilitating broader adoption.

Product portfolio and pipeline

• TriNav ADVANCE, a new product, enables use in smaller, tortuous vessels and allows physicians to use their preferred microcatheters.

• Awaiting imminent FDA clearance for TriNav ADVANCE, which will expand the addressable market by about 20%.

• Plans to introduce even smaller device sizes within 12–24 months, further broadening clinical applications.

• Full portfolio aims to provide interventional radiologists with tools for nearly all vascular anatomies.

Commercial strategy and sales force

• Recently doubled the sales force, with new hires halfway through their productivity ramp; peer-to-peer physician programs are accelerating adoption.

• Peer-to-peer events have increased two to three times in Q2, shortening the sales cycle and boosting awareness.

• Workflow for adoption is straightforward, mirroring standard microcatheter procedures, enabling rapid physician independence.

• Commercial expansion was executed rapidly to minimize disruption, though a more robust training program would be implemented in hindsight.